Document Classification

Section Type: METHODS

Text: Between November 1993 and September 2000, 307 patients were randomized to receive (following four cycles of epirubicin 90 mg/m (2) and cyclophosphamide 600 mg/m (2), intravenously every 21 days) either HD-CT of cyclophosphamide 1500 mg/m (2), thiotepa 150 mg/m (2), and mitoxantrone 10 mg/m (2), intravenously for 4 consecutive days followed by stem-cell support ; or SD-CT in three cycles of cyclophosphamide 500 mg/m (2), methotrexate 40 mg/m (2), and fluorouracil 600 mg/m (2) intravenously on days 1 and 8, every 28 days.